Dolutegravir/rilpivirine

Dolutegravir/rilpivirine, sold under the brand name Juluca, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.^[9][7] It contains the medicines dolutegravir and rilpivirine.^[7] It is taken by mouth.^[7]

Dolutegravir/rilpivirine

Combination of
Dolutegravir	HIV integrase strand transfer inhibitor (INSTI)
Rilpivirine	HIV non-nucleoside reverse-transcriptase inhibitor (NNRTI)
Clinical data
Trade names	Juluca
AHFS/Drugs.com	Monograph
License data	US DailyMed: Juluca
Pregnancy category	AU: B1[1][2]
Routes of administration	By mouth
ATC code	J05AR21 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[3][2] CA: ℞-only[4][5] UK: POM (Prescription only)[6] US: ℞-only[7] EU: Rx-only[8] In general: ℞ (Prescription only)
Identifiers
KEGG	D11282

The most common adverse reactions (of all severity grades) are diarrhea and headache.^[7]

Dolutegravir/rilpivirine was approved for use in the United States in November 2017,^[7][10][11] and for use in the European Union in May 2018.^[8]

Medical uses

Dolutegravir/rilpivirine is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.^[8]